MelissaLynneJohnsonMD

Thoracic Cancer

Director, Lung Cancer Research Associate Director, Drug Development Unit-Nashville Sarah Cannon Research Institute Tennessee Oncology, PLLC

Join to view full profile

Dr. Johnson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Johnson's full profile

Already have an account?

Office
250 25th Ave., N
Suite 200
Nashville, TN 37203
Phone+1 615-320-5090

Summary

Dr. Melissa Johnson is the Director of the Lung Cancer Research Program at Sarah Cannon Research Institute and the Associate Director of the Drug Development Unit in Nashville. She is also a partner in Tennessee Oncology, PLLC. She is a medical oncologist affiliated with TriStar Centennial Medical Center. She received her medical degree from Perelman School of Medicine at the University of Pennsylvania and has been in practice 13 years. She specializes in thoracic oncology and clinical trial investigation.

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2004 - 2007
Perelman School of Medicine at the University of PennsylvaniaClass of 2004

Certifications & Licensure

FL State Medical License 2020 - Present
TN State Medical License 2021 - 2025
LA State Medical License 2020 - 2022
AL State Medical License 2020 - 2020
IL State Medical License 2010 - 2017
NY State Medical License 2006 - 2011
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011

Clinical Trials

Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Start of enrollment: 2010 Oct 25
Completed
Phase 3
LDE225 for Patients With PTCH1 or SMO Mutated Tumors Start of enrollment: 2014 Feb 01
Terminated
Phase 2
A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer Start of enrollment: 2019 Apr 01
Active, not recruiting
Phase 1
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas Start of enrollment: 2019 Mar 26
Completed
Phase 1
A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) Start of enrollment: 2019 Sep 19
Active, not recruiting
Phase 2
A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation) Start of enrollment: 2019 Oct 28
Active, not recruiting
Phase 1
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors Start of enrollment: 2020 Dec 13
Recruiting
Phase 1, Phase 2
RBN-2397 in Combination With Pembrolizumab in Patients With SCCL Start of enrollment: 2022 Mar 15
Active, not recruiting
Phase 1, Phase 2
Roles: Principal Investigator
Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy Start of enrollment: 2020 Sep 11
Active, not recruiting
Phase 3
Roles: Contact
NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC Start of enrollment: 2021 Nov 03
Active, not recruiting
Phase 2
Roles: Contact, Principal Investigator
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities Start of enrollment: 2020 Dec 16
Recruiting
Phase 1, Phase 2
Roles: Contact
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations Start of enrollment: 2020 Jan 10
Active, not recruiting
Phase 3
Roles: Principal Investigator
Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors Start of enrollment: 2019 Aug 01
Recruiting
Phase 1
Roles: Contact, Principal Investigator
Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations Start of enrollment: 2022 Mar 31
Recruiting
Phase 1, Phase 2
Roles: Contact
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors Start of enrollment: 2020 Aug 19
Terminated
Phase 1, Phase 2
Roles: Contact
A Study of TAS3351 in NSCLC Patients With EGFRmt Start of enrollment: 2023 May 03
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

3 citations
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON ...
Solange Peters, Byoung Chul Cho, Alexander V Luft, Jorge Alatorre-Alexander, Sarayut Lucien Geater
Journal of Thoracic Oncology. 2025-01-01
Delayed Separation of Kaplan-Meier Curves is Commonly Observed in Studies of Advanced/Metastatic Solid Tumors Treated with Anti-PD-(L)1 Therapy: Systematic Review and ...
Do-Youn Oh, Nana Rokutanda, Magdalena Żotkiewicz, Philip He, Jennifer Stocks
Targeted Oncology. 2025-01-01
FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004).
Alexander Spira, Byoung Chul Cho, Enriqueta Felip, Edward B Garon, Koichi Goto
Lung Cancer. 2025-01-01

Lectures

A phase I, open label, multicenter dose escalation study of AZD2811 nanoparticle in patients with advanced solid tumors.
ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
A phase I, open-label, multicenter dose escalation study to assess the safety, tolerability, and pharmacokinetics of AZD2811 nanoparticle in patients with advanced sol...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
First in human phase 1/2a study of PEN-221 somatostatin analog (SSA)-DM1 conjugate for patients (PTS) with advanced neuroendocrine tumor (NET) or small cell lung cance...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Combination Chemotherapy Strategies in Frontline Therapy
2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
Join now to see all

Press Mentions

Arcus Biosciences Announces That Domvanalimab plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung CancerNovember 5th, 2024
Immunitas Therapeutics Announces First Patient Dosed in Phase 1/2a Study of IMT-009January 4th, 2023
Domvanalimab-Containing Regimens Show Activity in PD-L1-High NSCLCDecember 28th, 2022
Join now to see all